Case Report: 40-month durable deep molecular remission after blinatumomab + autologous HSCT in a high-risk B-ALL patient with HIV infection and triple risk factors
Year: 2026
Type: article
Study design: Case Report
Abstract: Background B-cell acute lymphoblastic leukemia (B-ALL) with human immunodeficiency virus (HIV) infection harboring concurrent high-risk genomic alterations represents an extremely rare and aggressive clinical entity with dismal prognosis. Patients living with HIV have been systematically excluded from clinical trials of bispecific T-cell engager immunotherapy, resulting in limited real-world evidence regarding safety and efficacy in this high-risk population. Case presentation On March 24, 2023, a 40-year-old man with well-controlled HIV infection presented with extreme hyperleukocytosis (309×10 9 /L), KMT2A::AFF1 (t(4;11)) rearrangement, and multiple TP53 mutations, defining a high-risk B-ALL with HIV infection and triple risk factors. After leukapheresis, cytoreduction, and vincristine, daunorubicin, cyclophosphamide, L-asparaginase, and prednisone (VDCLP) induction chemotherapy, he achieved complete molecular remission with undetectable measurable residual disease (MRD). Antiretroviral therapy (ART) was optimized to reduce drug–drug interactions and preserve immune competence. Risk-guided blinatumomab consolidation was well tolerated and maintained deep MRD negativity without HIV virologic breakthrough. The patient subsequently received intensive consolidation and autologous hematopoietic stem cell transplantation (auto-HSCT). Longitudinal immune profiling revealed treatment phase–dependent immune remodeling, including profound and sustained B-cell aplasia. At the last follow-up on August 4, 2026, more than 40 months post-diagnosis, he remains in sustained deep molecular remission with durable HIV suppression. Conclusion This case demonstrates that ART optimization, risk-guided blinatumomab consolidation, and auto-HSCT can safely and effectively achieve durable deep molecular remission in a high-risk B-ALL patient with HIV infection and triple risk factors, although the contributions of individual treatments remain uncertain. Longitudinal immune monitoring provides novel insights into immune reconstitution and therapeutic monitoring in this ultra-high-risk population.
Source: Frontiers in Oncology
Authors: Lingzhen Chen(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing), Yongmin Zhang(Data curation, Investigation, Validation, Writing – review & editing), Ting Zhong(Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing), Lanlan Jia(Conceptualization, Investigation, Resources, Supervision, Writing – review & editing), Manwen Tian(Data curation, Formal analysis, Validation, Writing – review & editing), Jing Ai(Conceptualization, Project administration, Resources, Supervision, Writing – review & editing), Junteng Chen(Supervision, Validation, Writing – review & editing), Jiaqin Peng(Data curation, Writing – review & editing)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7235522268
